Literature DB >> 31183807

Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies.

Vivian R Jaber1, Yuhai Zhao1,2, Nathan M Sharfman1, Wenhong Li1,3, Walter J Lukiw4,5,6.   

Abstract

Disruptions in multiple neurobiological pathways and neuromolecular processes have been widely implicated in the etiopathology of Alzheimer's disease (AD), a complex, progressive, and ultimately lethal neurological disorder whose current incidence, both domestically and globally, is reaching epidemic proportions. While only a few percent of all AD cases appear to have a strong genetic or familial component, the major form of this disease, known as idiopathic or sporadic AD, displays a multi-factorial pathology and represents one of the most complex and perplexing neurological disorders known. More effective and innovative pharmacological strategies for the successful intervention and management of AD might be expected: (i) to arise from strategic-treatments that simultaneously address multiple interrelated AD targets that are directed at the initiation, development, and/or propagation of this disease and (ii) those that target the "neuropathological core" of the AD process at early or upstream stages of AD. This "Perspectives paper" will review current research involving microRNA (miRNA)-mediated, messenger RNA (mRNA)-targeted gene expression pathways in sporadic AD and address the potential implementation of evolving anti-microRNA (AM) strategies in the amelioration and clinical management of AD. This novel-therapeutic approach: (i) incorporates a system involving the restoration of multiple miRNA-regulated mRNA-targets via the use of selectively-stabilized AM species; and (ii) that via implementation of synthetic AMs, the abundance of only relatively small-families of miRNAs need be modulated or neutralized to re-establish neural-homeostasis in the AD-affected brain. In doing so, these strategic approaches will jointly and interactively address multiple AD-associated processes such as the disruption of synaptic communication, defects in amyloid peptide clearance and amyloidogenesis, tau pathology, deficits in neurotrophic support, alterations in the innate immune response, and the proliferation of neuroinflammatory signaling.

Entities:  

Keywords:  Alzheimer’s disease; messenger RNA (mRNA); miRNA-125b; miRNA-146a; miRNA-155; miRNA-34a; miRNA-7; miRNA-9; miRNA-mRNA linkage analysis; microRNA (miRNA)

Mesh:

Substances:

Year:  2019        PMID: 31183807      PMCID: PMC6842093          DOI: 10.1007/s12035-019-1632-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  14 in total

1.  MicroRNA-34a Regulates the Depression-like Behavior in Mice by Modulating the Expression of Target Genes in the Dorsal Raphè.

Authors:  Luisa Lo Iacono; Donald Ielpo; Alessandra Accoto; Matteo Di Segni; Lucy Babicola; Sebastian Luca D'Addario; Fabio Ferlazzo; Tiziana Pascucci; Rossella Ventura; Diego Andolina
Journal:  Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.590

Review 2.  Promising Role of Oral Cavity Mesenchymal Stem Cell-Derived Extracellular Vesicles in Neurodegenerative Diseases.

Authors:  Masoumeh Pourhadi; Hakimeh Zali; Rasoul Ghasemi; Saeed Vafaei-Nezhad
Journal:  Mol Neurobiol       Date:  2022-07-22       Impact factor: 5.682

3.  MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints.

Authors:  Andrea Vergallo; Simone Lista; Yuhai Zhao; Pablo Lemercier; Stefan J Teipel; Marie-Claude Potier; Marie-Odile Habert; Bruno Dubois; Walter J Lukiw; Harald Hampel
Journal:  Transl Psychiatry       Date:  2021-01-27       Impact factor: 6.222

4.  The Role of Deregulated MicroRNAs in Age-Related Macular Degeneration Pathology.

Authors:  Hanan ElShelmani; Michael A Wride; Tahira Saad; Sweta Rani; David J Kelly; David Keegan
Journal:  Transl Vis Sci Technol       Date:  2021-02-05       Impact factor: 3.283

5.  P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.

Authors:  Zhenyu You; Dandan Peng; Yixin Cao; Yuanzhe Zhu; Jianjun Yin; Guangxing Zhang; Xiaodong Peng
Journal:  J Cell Mol Med       Date:  2021-09-12       Impact factor: 5.310

6.  Inflammatory Cytokine IL-1β Downregulates Endothelial LRP1 via MicroRNA-mediated Gene Silencing.

Authors:  Heng-Wei Hsu; Carlos J Rodriguez-Ortiz; Joannee Zumkehr; Masashi Kitazawa
Journal:  Neuroscience       Date:  2020-11-24       Impact factor: 3.590

7.  Facilitation of Gastrointestinal (GI) Tract Microbiome-Derived Lipopolysaccharide (LPS) Entry Into Human Neurons by Amyloid Beta-42 (Aβ42) Peptide.

Authors:  Walter J Lukiw; Wenhong Li; Taylor Bond; Yuhai Zhao
Journal:  Front Cell Neurosci       Date:  2019-12-06       Impact factor: 5.505

Review 8.  microRNA-Based Biomarkers in Alzheimer's Disease (AD).

Authors:  Yuhai Zhao; Vivian Jaber; Peter N Alexandrov; Andrea Vergallo; Simone Lista; Harald Hampel; Walter J Lukiw
Journal:  Front Neurosci       Date:  2020-10-30       Impact factor: 4.677

Review 9.  Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer's Disease.

Authors:  Xuewen Xiao; Xixi Liu; Bin Jiao
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

10.  MicroRNA-Target Interaction Regulatory Network in Alzheimer's Disease.

Authors:  Aleksander Turk; Tanja Kunej; Borut Peterlin
Journal:  J Pers Med       Date:  2021-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.